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Abstract
Background: The aims were to analyze two novel NOD2 variants (rs2066843 and rs2076756) in a large cohort of patients
with inflammatory bowel disease and to elucidate phenotypic consequences.
Methodology/Principal Findings: Genomic DNA from 2700 Caucasians including 812 patients with Crohn’s disease (CD),
442 patients with ulcerative colitis (UC), and 1446 healthy controls was analyzed for the NOD2 SNPs rs2066843 and
rs2076756 and the three main CD-associated NOD2 variants p.Arg702Trp (rs2066844), p.Gly908Arg (rs2066847), and
p.Leu1007fsX1008 (rs2066847). Haplotype and genotype-phenotype analyses were performed. The SNPs rs2066843
(p=3.01610
25, OR 1.48, [95% CI 1.23-1.78]) and rs2076756 (p=4.01610
26; OR 1.54, [95% CI 1.28-1.86]) were significantly
associated with CD but not with UC susceptibility. Haplotype analysis revealed a number of significant associations with CD
susceptibility with omnibus p values ,10
210. The SNPs rs2066843 and rs2076756 were in linkage disequilibrium with each
other and with the three main CD-associated NOD2 mutations (D’.0.9). However, in CD, SNPs rs2066843 and rs2076756
were more frequently observed than the other three common NOD2 mutations (minor allele frequencies for rs2066843 and
rs2076756: 0.390 and 0.380, respectively). In CD patients homozygous for these novel NOD2 variants, genotype-phenotype
analysis revealed higher rates of a penetrating phenotype (rs2076756: p=0.015) and fistulas (rs2076756: p=0.015) and
significant associations with CD-related surgery (rs2076756: p=0.003; rs2066843: p=0.015). However, in multivariate
analysis only disease localization (p,2610
216) and behaviour (p=0.02) were significantly associated with the need for
surgery.
Conclusion/Significance: The NOD2 variants rs2066843 and rs2076756 are novel and common CD susceptibility gene
variants.
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Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic
inflammatory bowel diseases (IBD) characterized by an exaggerated
immune response of the intestinal mucosa and a dysfunctional
epithelial barrier [1,2,3,4]. The identification of nucleotide-binding
oligomerization domain 2 (NOD2, GeneID: 64127), also known as
caspase recruitment domain-containing protein 15 (CARD15) as the
first susceptibility gene in CD in 2001 [5,6] has provided significant
new insights in the pathogenesis of IBD focusing on the genetic
background of innate immune response and interaction with
bacterial antigens [7,8,9,10]. Most recently, genome-wide associa-
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further insights into IBD pathogenesis by identification and
confirmation of susceptibility genes such as the interleukin-23
receptor (IL23R) [11,12], SLC22A4/5 [13] and ATG16L1 [14]
(autophagy-related 16-like 1) gene.
NOD2 represents a cytoplasmatic protein and functions mainly
as a NF-kB pathway activating sensor for bacterial muramyl
dipeptide (MDP) found in the cell wall of Gram-positive and
Gram-negative bacteria [8,15,16,17]. In addition, NOD2 seems to
be a negative regulator of Toll-like receptor 2-mediated T helper
cell type 1 responses and modulates ileal expression of antimicro-
bial peptides such as alpha-defensins and the expression of
proinflammatory cytokines and chemokines in the intestinal
mucosa [18,19,20]. The identification of NOD2 as a susceptibility
gene for CD therefore suggests an important role of genetically
determined enteric bacteria-host interactions and an inappropriate
activation of the mucosal immune system in IBD. Large genotype-
phenotype analyses by us [21,22] and others [23,24,25] also
demonstrated a significant association of NOD2 variants with ileal
involvement, stricturing phenotype and early disease onset in CD
patients.
The NOD2 gene is located on chromosome 16q in the IBD1
locus and contains 11 constant exons and a twelfth alternatively
spliced exon in the 59-region. So far, three main NOD2 variants,
which include two amino acid substitutions, p.Arg702Trp encoded
by exon 4, and p.Gly908Arg encoded by exon 8, and the
frameshift mutation p.Leu1007fsX1008 located in exon 11, were
identified to be overrepresented in CD patients. There is also
evidence for further NOD2 variants being involved in IBD
pathogenesis as demonstrated by us [26] and others in recent
association studies [18,19,20]. However, the extent of disease
modification or phenotypic consequences of other NOD2 variants
such as the SNPs rs2066843 and rs2076756 have not been
investigated so far.
We therefore genotyped 2700 individuals of Caucasian origin
and performed a large and detailed genotype-phenotype analysis
for the NOD2 variants rs2066843 and rs2076756 analyzing the
influence of these variants on the disease susceptibility and
phenotype of patients with CD and UC.
Materials and Methods
Study population
The study population (n=2700) was comprised of 1254 IBD
patients of Caucasian origin including 812 patients with CD, 442
patients with UC, and 1446 healthy, unrelated controls. The
patients were recruited in two cohorts; the discovery sample was
recruited from the University Hospital Munich-Grosshadern and
comprised 519 CD patients, 232 UC patients and 770 controls,
while the replication cohort recruited from the University
Hospitals Bochum and Munich-Innenstadt consisted of 293 CD
patients, 210 UC patients and 676 controls. Patients with
indeterminate colitis were excluded from the study. All individuals
gave written, informed consent prior to the study. The study was
approved by the local Ethics committee and adhered to the ethical
principles for medical research involving human subjects of the
Helsinki Declaration. Phenotypic parameters were collected blind
to the results of the genotype analysis and included demographic
and clinical data (behaviour and anatomic location of IBD,
disease-related complications, surgical or immunosuppressive
therapy). Two senior gastroenterologists analyzed data which
were recorded by patient charts analysis and a detailed
questionnaire based on an interview at time of enrolment. For
the analysis of demographic and phenotypic data, the diagnosis of
CD and UC was related to established international guidelines
based on endoscopic, radiological, and histopathological param-
eters [27]. CD patients were classified according to the Montreal
classification [28] including age at diagnosis (A), location (L), and
behaviour (B) of disease. In patients with UC, anatomic location
was also assessed in accordance to the Montreal classification
based on the criteria ulcerative proctitis (E1), left-sided UC (distal
UC; E2), and extensive UC (pancolitis; E3). The clinical
characteristics of the IBD study population are summarized in
Table 1.
DNA extraction and NOD2 genotyping
Genomic DNA was isolated from peripheral blood leukocytes
by standard procedures using the DNA blood mini kit from
Qiagen (Hilden, Germany). Genotyping of the NOD2 variants
p.Arg702Trp (rs2066844), p.Gly908Arg (rs2066847), and
p.Leu1007fsX1008 (rs2066847) were performed as described
previously [26] (primer and probe sequences are available on
request). The NOD2 SNPs rs2066843 and rs2076756 were
genotyped by PCR and melting curve analysis using a pair of
fluorescence resonance energy transfer (FRET) probes, a sensor
and an anchor probe, respectively, in a LightCycler 480
Instrument (Roche Diagnostics, Mannheim, Germany). The
donor fluorescent molecule (fluorescein) at 39-end of the sensor
probe in case of rs2066843 or the anchor probe in case of
rs2076756, respectively, is excited at its specific fluorescence
excitation wavelength (533 nm) and the energy is transferred to
the acceptor fluorescent molecule at the 59-end of the anchor
probe in case of rs2066843 (LightCycler Red 640) or the sensor
probe in case of rs2076756 (LightCycler Red 670). The specific
fluorescence signal emitted by the acceptor molecule is detected by
the optical unit of the LightCycler 480 Instrument. The sensor
probe is exactly matching to one allele of each SNP, whereas in the
case of the other allele there is a mismatch resulting in a lower
melting temperature. The total volume of the PCR was 5 ml
containing 25 ng of genomic DNA, 1 x Light Cycler 480
Table 1. Demographic characteristics of the IBD study
population.
Crohn’s disease
n=812
Ulcerative colitis
n=442
Controls
n=1446
Gender
Male (%)
Female (%)
49.0
51.0
48.1
51.9
63.1
36.9
Age (yrs)
Mean 6 SD
Range
39.4613.2
10-80
41.7614.6
7–85
46.1610.6
18–71
Body mass index
Mean 6 SD
Range
23.164.1
13–40
23.964.2
15–41
Age at diagnosis
(yrs)
Mean 6 SD
Range
27.5611.5
7–71
32.1613.5
9–81
Disease duration
(yrs)
Mean 6 SD
Range
12.268.5
0–44
11.067.8
1–40
Positive family
history of IBD (%)
16.2 16.1
doi:10.1371/journal.pone.0014466.t001
Novel NOD2 Variants in IBD
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and 0.75 pmol of each FRET probe (TIB MOLBIOL, Berlin,
Germany). The PCR comprised an initial denaturation step
(95uC for 10 min) and 45 cycles (95uC for 10 sec, primer
annealing temperature as given in Supplemental Table S1 for
10 sec, 72uC for 15 sec). The melting curve analysis comprised
an initial denaturation step (95uC for 1 min), a step rapidly
lowering the temperature to 40uC and holding for 60 sec, and a
heating step slowly (1 acquisition/uC) increasing the temperature
up to 95uC and continuously measuring the fluorescence
intensity. The results of melting curve analysis had been
confirmed by analyzing samples representing all possible
genotypes using sequence analysis. For sequencing, the total
volume of the PCR was 100 ml containing 250 ng of genomic
DNA, 1 x PCR-buffer (Qiagen, Hilden, Germany), a final MgCl2
concentration of 1.5 mM, 0.5 mM of a dNTP-Mix (Sigma,
Steinheim, Germany), 2.5 units of HotStar Plus Taq
TM DNA
polymerase (Qiagen) and 10 pmol of each primer (TIB
MOLBIOL, Berlin, Germany). The PCR used for sequencing
comprised an initial denaturation step (95uC for 5 min), 35 cycles
(denaturation at 94uC for 30 sec, primer annealing at 60uCf o r
30 sec, extension at 72uC for 30 sec) and a final extension step
(72uC for 10 min). The PCR products were purified using the
QIAquick PCR Purification Kit (Qiagen) and sequenced by a
commercial sequencing company (Sequiserve, Vaterstetten,
Germany). All sequences of primers and FRET probes and
primer annealing temperatures used for genotyping and for
sequence analysis are given in the supplementary data section
(Supplemental Table S1 and S2). The results of the genotyping
for the CD-associated ATG16L1 variant rs2241880 (p.Thr300Ala)
were available from a previous study [29].
Statistical analyses
Each genetic marker was tested for Hardy-Weinberg equilib-
rium in the control population. Fisher’s exact test or x
2 test for
comparison between categorical variables were used where
appropriate. Single-marker allelic tests were performed with
Pearson’s x
2 test. Student’s t-test was applied for quantitative
variables. All tests were two-tailed and p-values ,0.05 were
considered significant. Odds ratios were calculated for the minor
allele at each SNP. For evaluation of phenotypic consequences, we
conducted a logistic regression analysis. Data were evaluated by
using the SPSS 13.0 software (SPSS Inc., Chicago, IL, U.S.A.) and
R-2.4.1. (http://cran.r-project.org). Haplotype analysis and cal-
culation of linkage disequilibrium (LD) were conducted using
PLINK (http://pngu.mgh.harvard.edu/,purcell/plink/).
Results
The novel NOD2 variants rs2066843 and rs2076756 are
associated with susceptibility to CD but not to UC
In the controls, the genotype frequencies of the SNPs rs2066843
and rs2076756 were in agreement with the predicted Hardy-
Weinberg equilibrium. Significant differences in the allele
frequencies of the SNPs rs2066843 and rs2076756 were observed
in CD patients but not in UC patients compared to healthy
controls. As summarized in Table 2, the SNPs rs2066843 and
rs2076756 were strongly associated with CD. In the group of CD
patients, the frequency of the rarer T allele of the rs2066843
variant was 0.390, whereas in the controls it was 0.299
(p=3.01610
25; OR 1.48, [95% CI 1.23-1.78]). The frequencies
of the less common G allele of the rs2076756 variant were 0.390 in
CD and 0.286 in the controls (p=4.01610
26; OR 1.54, [95% CI
1.28-1.86]). In contrast to CD, no associations of both NOD2 SNPs
were observed in UC. The frequency of the rs2066843 T allele
was 0.300 (p=9.67610
21, OR 1.01 [95% CI 0.85-1.19]), while
the frequency of the rs2076756 G allele was 0.270 (p=3.74610
21,
OR 1.09 [95% CI 0.94-1.27]). The association of the NOD2 SNPs
with CD susceptibility was found in both our initial discovery
cohort from the University Hospital Munich-Grosshadern (Sup-
plemental Table S3) and the replication cohort from the
University Hospital Munich, Campus Innenstadt and from
Ruhr-University Bochum (Supplemental Table S4). In this study,
rs2066843 and rs2076756 were in LD in all studied subpopula-
tions (CD, UC, healthy controls; Supplemental Tables S5, S6, S7).
To analyze for potential disease associations with certain NOD2
haplotypes, we performed a detailed haplotype analysis (Table 3
and Supplemental Table S8). As shown in Table 3, we
demonstrated for a number of haplotypes significant associations
with CD susceptibility, including several associations with omnibus
p values of less than 10
210. The strongest association of a
haplotype including one of the SNPs rs2066843 or rs2076756
comprised of the NOD2 SNPs rs2066844-rs2066845-rs2066847-
rs2076756 (omnibus p-value =1.14610
223). In contrast, no
significant associations were found with UC susceptibility
(Supplemental Table S8).
Genotype-phenotype analysis of rs2066843 and
rs2076756 NOD2 variants in CD patients
Since the three common NOD2 variants p.Arg702Trp
(rs2066844), p.Gly908Arg (rs2066847), and p.Leu1007fsX1008
(rs2066847) have been identified to be associated with a certain
CD phenotype [21,22,23,24,30], we also performed a detailed
Table 2. Allele frequencies of the SNPs rs2066843 and rs2076756 in patients with Crohn’s disease, ulcerative colitis and controls.
Gene marker
Minor
allele
Crohn’s disease
n=812
Ulcerative colitis
n=442
Controls
n=1446
MAF p value OR [95% CI] MAF p value OR [95% CI] MAF
rs2066843 T 0.390 3.01610
25 1.48 [1.23–1.78] 0.300 9.67610
21 1.01 [0.85–1.19] 0.299
rs2076756 G 0.380 4.01610
26 1.54 [1.28–1.86] 0.270 3.74610
21 1.09 [0.94–1.27] 0.286
rs2066844 p.Arg702TrpT 0.089 1.43610
26 2.07 [1.53–2.79] 0.046 7.49610
21 0.92 [0.60–1.40] 0.050
rs2066845 p.Gly908ArgG 0.042 1.1610
22 1.72 [1.14–2.60] 0.022 1.00 0.94 [0.51–1.73] 0.024
rs2066847
p.Leu1007fsX1008
insC 0.121 1.88610
214 5.03 [3.54–7.15] 0.022 3.91610
21 0.76 [0.42–1.37] 0.028
Minor allele frequencies (MAF), allelic test P-values, and odds ratios (OR, shown for the minor allele) with 95% confidence intervals (CI) are depicted for both the CD and
UC case-control cohorts.
doi:10.1371/journal.pone.0014466.t002
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NOD2 haplotypes p-value OR CI lower CI upper
rs2066843-rs2066844 1.31610
28
TT 1.34610
25 1.94 1.81 2.08
TC 3.09610
24 1.34 1.28 1.40
CC 1.72610
28 0.65 0.63 0.66
rs2066844-rs2066845 7.94610
28
CC 3.25610
23 1.80 1.58 2.06
TG 3.80610
26 1.89 1.78 2.00
CG 1.08610
28 0.52 0.50 0.54
rs2066845-rs2066847 1.09610
218
GC 6.88610
217 4.06 3.90 4.22
CX 6.67610
23 1.74 1.50 2.02
GX 4.38610
220 0.32 0.31 0.33
rs2066847-rs2076756 2.48610
215
CG 2.88610
214 3.84 3.67 4.02
XG 3.31610
21 1.09 0.91 1.30
XA 2.35610
29 0.62 0.61 0.64
rs2066843-rs2066844-rs2066845 5.94610
210
TCC 1.16610
23 1.90 1.69 2.14
TTG 8.40610
27 2.01 1.90 2.13
TCG 2.64610
22 1.21 1.12 1.31
CCG 9.68610
210 0.62 0.61 0.64
rs2066844-rs2066845-rs2066847 8.22610
224
CGC 5.84610
217 4.07 3.91 4.23
CCX 1.08610
22 1.70 1.45 1.99
TGX 3.59610
26 1.89 1.78 2.00
CGX 4.19610
226 0.37 0.36 0.37
rs2066845-rs2066847-rs2076756 2.48610
215
GCG 5.41610
217 4.09 3.93 4.25
CXG 1.04610
23 1.94 1.72 2.19
GXG 3.47610
21 0.92 0.76 1.11
GXA 3.89610
212 0.59 0.57 0.60
rs2066843-rs2066844-rs2066845-rs2066847 1.60610
223
TCGC 4.10610
217 4.28 4.11 4.46
TCCX 1.18610
23 1.90 1.69 2.14
TTGX 8.51610
27 1.99 1.88 2.10
TCGX 2.32610
25 0.66 0.63 0.69
CCGX 8.57610
213 0.59 0.58 0.60
rs2066844-rs2066845-rs2066847-rs2076756 1.14610
223
CGCG 5.20610
217 4.04 3.89 4.20
CCXG 1.10610
23 1.93 1.71 2.18
TGXG 4.75610
27 2.06 1.95 2.18
CGXG 1.24610
25 0.642 0.61 0.67
CGXA 7.82610
213 0.59
rs2066843-rs2066844-rs2066845-rs2066847-rs2076756 1.43610
221
TCGCG 6.33610
217 4.18 4.02 4.35
TCCXG 1.07610
23 1.93 1.71 2.18
TTGXG 6.00610
27 2.05 1.94 2.17
TCGXG 9.42610
25 0.67 0.64 0.71
TCGXA 6.48610
22 0.576 0.42 0.79
CCGXA 2.01610
211 0.61 0.60 0.63
Omnibus as well as individual p-values are presented.
doi:10.1371/journal.pone.0014466.t003
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analysis, CD patients homozygous for the SNP rs2066843 were
found to have a lower body mass index (p=0.039) and less
colonic involvement (p=0.041) compared to the wildtype
patients and we observed also a trend towards a predominantly
penetrating disease phenotype (B3) (p=0.068; Table 4). In
addition, a higher need for CD-related surgery in homozygous
carriers of the SNP rs2066843 (p=0.015) was observed
compared to the wildtype group (Table 5).
Analyzing CD patients regarding the rs2076756 genotype
status, a significant younger age at disease onset was observed in
homozygous carriers (mean 25.8611.4 years) compared to
wildtype patients (p=0.023; Table 6). Similar to the analysis of
SNP rs2066843, homozygous carriers of SNP rs2076756 had less
colonic involvement than wildtype patients (p=0.032) but showed
a trend towards ileocolonic disease location (p=0.058) and had a
significant higher rate of penetrating disease phenotype (B3)
(p=0.015; Table 6). The significant association of SNP rs2076756
with a severe disease phenotype was also reflected by the
significantly higher percentage of patients with CD-related surgery
(p=0.003) and internal fistulas (p=0.015) in homozygous carriers
of this SNP (Table 7). Moreover, there was also a trend towards
stenotic complications (p=0.067) in homozygous CD patients
(Table 7). However, given the large number of associations
investigated, most associations lost significance following Bonfer-
roni correction.
Given the increased prevalence of the three common NOD2
variants among carriers of the risk allele of rs2066843 and
rs2076756 and previous reports demonstrating a severe pheno-
type in carriers of these three NOD2 variants, we next investigated
if the phenotypic effects of rs2066843 and rs2076756 were
independent of the main three CD-associated NOD2 variants
p.Arg702Trp (rs2066844), p.Gly908Arg (rs2066847), and
p.Leu1007fsX1008 (rs2066847). As shown in Table 8, there
were no significant differences regarding homozygous carriers of
these SNPs when stratified for the presence and absence of the
main three CD-associated NOD2 variants and the significant
phenotypic characteristics found in Tables 5, 6 and 7, suggesting
that the CD-modifying effect of rs2066843 and rs2076756 is
independent of the three main NOD2 variants.
Analyzing potential therapeutic consequences such as need for
surgery, we next conducted a logistic regression analysis with R,
using the need for surgery as dependent variable, and the SNP
genotype as independent variable, taking localization as well as
behaviour as covariates. This revealed that disease localization has
a significant influence on the need for surgery (p=0.02). In
addition, disease behaviour is significantly associated with the need
for surgery (p=2.0610
216, independently of localization). How-
ever, using the NOD2 genotype status as further explanatory
variable does not improve the model fit (F-test p=0.36 rs2066843,
p=0.32 rs2076756).
In UC patients, the analysis revealed no significant associations
of the SNPs rs2066843 and rs2076756 with phenotypic charac-
teristics such as age, age a diagnosis, male-to-female-ratio, body
mass index (BMI), family history, anatomic location and disease
behaviour, use of immunosuppressive agents, or UC-related
complications (data not shown).
No evidence for epistasis between NOD2 variants and
the CD-associated ATG16L1 variant rs2241880
(p.Thr300Ala)
Very recent studies indicate that NOD2 recruits the
autophagy protein ATG16L1 to the plasma membrane at the
bacterial entry site [31]. In contrast, CD-associated mutants
failed to recruit ATG16L1 to the plasma membrane and
wrapping of invading bacteria by autophagosomes was impaired
[31]. Moreover, dendritic cells from CD patients expressing
Table 4. Association between rs2066843 genotype and CD disease characteristics based on the Montreal classification [28].
rs2066843 genotype
status
(1)
CC
n=322
(2)
CT
n=345
(3)
TT
n=150
(1) vs. (2)
p-value
OR [95% CI]
(1) vs. (3)
p-value
OR [95% CI]
(1) vs. (2) + (3)
p-value
OR [95% CI]
Age at diagnosis
#16 years (A1)
17–40 years (A2)
.40 years (A3)
74/239 (31.0%)
150/239 (62.8%)
15/239 (6.2%)
81/237 (34.2%)
125/237 (52.7%)
31/237 (13.1%)
37/116 (31.9%)
69/116 (59.5%)
10/116 (8.6%)
0.494
1.16 (0.79–1.70)
0.033
0.66 (0.46–0.95)
0.013
2.25 (1.18–4.28)
0.903
1.04 (0.65–1.68)
0.562
0.87 (0.55–1.37)
0.507
1.41 (0.61–3.24)
0.591
1.12 (0.79–1.59)
0.062
0.72 (0.52–1.01)
0.032
1.96 (1.06–3.63)
Location
Terminal ileum (L1)
Colon (L2)
Ileocolon (L3)
Upper GI (L4)
Any ileal involvement
(L1+L3)
32/244 (13.1%)
42/244 (17.2%)
166/244 (67.9%)
4/244 (1.6%)
198/244 (81.1%)
46/238 (19.3%)
33/238 (13.9%)
155/238 (65.1%)
4/238 (1.7%)
201/238 (84.5%)
12/120 (10.0%)
11/120 (9.2%)
93/120 (77.5%)
4/120 (3.3%)
105/120 (87.5%)
0.083
1.59 (0.97–2.59)
0.318
0.77 (0.47–1.27)
0.501
0.88 (0.60–1.28)
1.000
1.03 (0.25–4.15)
0.398
1.26 (0.78–2.03)
0.494
0.74 (0.36–1.49)
0.041
0.48 (0.24–0.98)
0.066
1.62 (0.98–2.68)
0.447
2.07 (0.51–8.42)
0.138
1.63 (0.87–3.05)
0.352
1.28 (0.80–2.04)
0.097
0.67 (0.43–1.07)
0.788
1.06 (0.75–1.50)
0.770
1.37 (0.41–4.61)
0.177
1.37 (0.88–2.11)
Behaviour
1
Non-stricturing,Non-
penetrat. (B1)
Stricturing (B2)
Penetrating (B3)
49/232 (21.1%)
66/232 (28.4%)
117/232 (50.4%)
61/233 (26.2%)
64/233 (27.5%)
108/233 (46.3%)
18/116 (15.5%)
27/116 (23.3%)
71/116 (61.2%)
0.230
1.32 (0.86–2.04)
0.837
0.95 (0.63–1.43)
0.404
0.85 (0.59–1.22)
0.249
0.69 (0.38–1.24)
0.368
0.76 (0.45–1.28)
0.068
1.55 (0.98–2.44)
0.684
1.09 (0.73–1.63)
0.567
0.89 (0.61–1.29)
0.866
1.03 (0.74–1.44)
1Disease behaviour was defined according to the Montreal classification [28]. Stricturing disease phenotype was defined as presence of stenosis without penetrating
disease. The diagnosis of stenosis was made surgically, endoscopically, or radiologically (using MR enteroclysis). For each variable, the number of patients included is
given.
doi:10.1371/journal.pone.0014466.t004
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autophagy induction, bacterial trafficking and antigen presen-
tation [32]. We therefore hypothesized that there may be
epistasis between CD-associated NOD2 and ATG16L1 variants
regarding susceptibility to CD. However, as shown in Supple-
mental Table S9, none of the 5 CD-associated NOD2 variants
showed evidence for epistasis to the CD-associated ATG16L1
variant rs2241880 (p.Thr300Ala).
Table 5. Association between rs2066843 genotype and CD disease characteristics.
rs2066843 genotype
status
(1)
CC
n=322
(2)
CT
n=345
(3)
TT
n=150
(1) vs. (2)
p-value
OR [95% CI]
(1) vs. (3)
p-value
OR [95% CI]
(1) vs. (2) + (3)
p-value
OR [95% CI]
Male sex 129/277 (46.6%) 153/289 (52.9%) 74/134 (55.2%) 0.131
1.29 (0.93–1.80)
0.115
1.41 (0.94–2.14)
0.075
1.33 (0.98–1.80)
Age at diagnosis (yrs)
Mean 6 SD
Range
27.1610.9
11–70
28.7612.5
1–78
25.8611.3
6–71
0.151 0.302 0.526
Disease duration (yrs)
Mean 6 SD
Range
12.368.4
0–37
11.469.0
11–44
11.868.2
1–35
0.381 0.675 0.403
Body mass index (yrs)
Mean 6 SD
Range
23.364.4
16–40
23.464.0
16–37
22.063.6
13–31
0.845 0.039 0.473
Use of
immunosuppressive
agents
2
141/169 (83.4%) 135/175 (77.1%) 70/83 (84.3%) 0.176
0.67 (0.39–1.15)
1.000
1.07 (0.52–2.19)
0.316
0.77 (0.46–1.27)
Surgery because of CD
3 113/221 (51.1%) 120/224 (53.6%) 76/116 (65.5%) 0.636
1.10 (0.76–1.60)
0.015
1.82 (1.14–2.89)
0.140
1.30 (0.93–1.83)
Fistulas 117/232 (50.4%) 108/233 (46.3%) 71/116 (61.2%) 0.404
0.85 (0.59–1.22)
0.068
1.55 (0.98–2.44)
0.866
1.03 (0.74–1.44)
Perianal fistulas 24/92 (26.1%) 18/90 (20.0%) 7/49 (14.3%) 0.212
1.41 (0.70–2.83)
0.079
2.12 (0.84–5.34)
0.096
1.61 (0.85–3.04)
Stenosis 140/229 (61.1%) 144/233 (61.8%) 80/115 (69.6%) 0.924
1.03 (0.71–1.50)
0.153
1.45 (0.90–2.34)
0.481
1.15 (0.81–1.62)
2Immunosuppressive agents included azathioprine, 6-mercaptopurine, 6-thioguanine, methotrexate, and/or infliximab.
3Only surgery related to CD-specific problems (e.g. fistulectomy, colectomy, ileostomy) was included. For each variable, the number of patients included is given.
doi:10.1371/journal.pone.0014466.t005
Table 6. Association between rs2076756 genotype and CD disease characteristics based on the Montreal classification [28].
rs2076756 genotype
status
(1)
AA
n=339
(2)
AG
n=334
(3)
GG
n=143
(1) vs. (2)
p-value
OR [95% CI]
(1) vs. (3)
p-value
OR [95% CI]
(1) vs. (2) + (3)
p-value
OR [95% CI]
Age at diagnosis
#16 years (A1)
17–40 years (A2)
.40 years (A3)
73/241(30.3%)
154/241(63.9%)
14/241 (5.8%)
75/233 (32.2%)
124/233 (53.2%)
34/233 (14.6%)
35/110 (31.8%)
66/110 (60.0%)
9/110 (8.2%)
0.692
1.09 (0.74–1.61)
0.020
0.64 (0.44–0.93)
0.002
2.77 (1.44–5.31)
0.804
1.07 (0.66–1.75)
0.552
0.85 (0.53–1.35)
0.486
1.44 (0.61–3.45)
0.717
1.09 (0.76–1.55)
0.041
0.70 (0.50–0.98)
0.007
2.32 (1.24–4.35)
Location
Terminal ileum (L1)
Colon (L2)
Ileocolon (L3)
Upper GI (L4)
Ileocolonic
Involvement
31/245 (12.7%)
41/245 (16.7%)
169/245 (70.0%)
4/245 (1.6%)
200/245 (81.6%)
45/235 (19.1%)
34/235 (14.5%)
152/235 (64.7%)
4/235 (1.7%)
197/235 (83.8%)
11/113 (9.7%)
9/113 (8.0%)
89/113 (78.8%)
4/113 (3.5%)
100/113 (88.5%)
0.061
1.63 (0.99–2.69)
0.531
0.84 (0.51–1.38)
0.333
0.82 (0.56–1.20)
1.000
1.04 (0.26–4.22)
0.548
1.17 (0.73–1.87)
0.483
0.74 (0.36–1.54)
0.032
0.43 (0.20–0.92)
0.058
1.67 (0.99–2.82)
0.268
2.21 (0.54–9.00)
0.123
1.73 (0.89–3.36)
0.289
1.32 (0.82–2.12)
0.151
0.70 (0.44–1.11)
1.000
1.01 (0.71–1.44)
0.769
1.48 (0.42–4.76)
0.258
1.31 (0.84–2.03)
Behaviour
1
Non-stricturing,
Non-penetrat. (B1)
Stricturing (B2)
Penetrating (B3)
49/232 (21.1%)
67/232 (28.9%)
116/232 (50.0%)
64/231 (27.7%9
61/231 (26.4%)
106/231 (45.9%)
12/109 (11.0%)
27/109 (24.8%)
70/109 (64.2%)
0.106
1.43 (0.93–2.19)
0.604
0.88 (0.59–1.33)
0.403
0.85 (0.59–1.22)
0.023
0.46 (0.23–0.91)
0.516
0.81 (0.48–1.36)
0.015
1.79 (1.12–2.87)
0.758
1.07 (0.72–1.61)
0.444
0.86 (0.59–1.25)
0.733
1.07 (0.77–1.50)
doi:10.1371/journal.pone.0014466.t006
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The identification of NOD2 as the first CD susceptibility gene in
2001 represents a landmark finding that implicated bac-
terial recognition and innate immunity as key processes involved
in the pathogenesis of CD. Since genotype-phenotype ana-
lyses of the NOD2 variants p.Arg702Trp, p.Gly908Arg, and
p.Leu1007fsX1008 have also provided strong evidence for the
existence of a NOD2-related CD phenotype, these studies have not
only changed our understanding of IBD pathogenesis but have
also implications for clinical practice [21,22,23,25].
Here, we investigated the two novel CD-associated NOD2
variants rs2066843 and rs2076756 in a large German IBD patient
cohort, confirming these NOD2 variants as susceptibility gene
variants for CD but not for UC. We could demonstrate a highly
significant association of SNPs rs2066843 and rs2076756 with CD.
The haplotype analysis revealed a number of significant
associations with CD susceptibility, including several associations
with omnibus p values of less than 10
210.
In addition, for the first time, our genotype-phenotype analysis
revealed a significant association of the SNPs rs2066843 and
rs2076756 with phenotypic characteristics such as early disease
onset, severe penetrating disease phenotype complicated by
fistulas. Moreover, univariante analysis revealed a frequent need
for CD-related surgery associated with SNPs rs2066843 and
rs2076756 in CD patients. However, the two novel CD-
associated NOD2 variants could not be identified as independent
variables for the need for surgery in CD patients after logistic
regression analysis, suggesting that ileal disease localization and a
stricturing or penetrating phenotype are clinically more relevant
predictors for the need for CD-related surgery than the NOD2
genotypes alone. In addition, the strength of the association of
rs2066843 and rs2076756 with CD was less pronounced than
that of the NOD2 variant rs2066847 (p.Leu1007fsX1008) which
results in patients homozygous for this variant in a more severe
phenotype [21,22] than found for rs2066843 and rs2076756 in
this study. Early deep-sequencing studies of the NOD2 locus by
the Hugot group also suggested that the NOD2 ‘‘gene-dosage’’
effect is more important in the CD phenotype development than
the type of NOD2 mutation
25. In the study by the Hugot group,
patients with ‘‘double-dose’’ NOD2 mutations (homozygous or
compound heterozygous) were characterized by a younger age at
onset, a more frequent stricturing phenotype, and less frequent
colonic involvement than were seen in those patients who had no
mutation
25.
Table 7. Association between rs2076756 genotype and CD disease characteristics.
rs2076756 genotype
status
(1)
AA
n=339
(2)
AG
n=334
(3)
GG
n=143
(1) vs. (2)
p-value
OR [95% CI]
(1) vs. (3)
p-value
OR [95% CI]
(1) vs. (2) + (3)
p-value
OR [95% CI]
Male sex 129/280 (46.1%) 152/283 (53.7%) 69/127 (54.3%) 0.077
1.36 (0.75–1.89)
0.135
1.39 (0.91–2.12)
0.044
1.37 (1.01–1.86)
Age at diagnosis (yr)
Mean 6 SD
Range
26.8610.5
11–70
29.2612.7
1–78
25.8611.4
6–71
0.023 0.465 0.157
Disease duration (yr)
Mean 6 SD
Range
12.468.4
0–37
11.268.8
1–44
11.668.2
1–35
0.188 0.507 0.202
Body mass index (yr)
Mean 6 SD
Range
23.4610.5
11–70
23.264.0
16–37
22.363.7
13–31
0.691 0.074 0.309
Use of immunosuppressive
agents
2
147/174 (84.5%) 136/176 (77.3%) 65/80 (81.2%) 0.103
0.62 (0.36–1.07)
0.586
0.80 (0.40–1.59)
0.134
0.67 (0.40–1.11)
Surgery because of CD
3 114/221 (51.6%) 120/222 (54.1%) 76/110 (69.1%) 0.635
1.10 (0.76–1.60)
0.003
2.10 (1.29–3.40)
0.097
1.35 (0.96–1.91)
Fistulas 116/232 (50.0%) 106/231 (45.9%) 70/109 (64.2%) 0.403
0.85 (0.59–1.22)
0.015
1.79 (1.12–2.87)
0.733
1.07 (0.77–1.50)
Perianal fistulas 21/95 (22.1%) 21/90 (23.3%) 5/47 (10.6%) 0.646
0.93 (0.47–1.86)
0.073
2.38 (0.84–6.79)
0.337
1.21 (0.64–2.31)
Stenosis 142/229 (62.0%) 139/230 (60.4%) 79/109 (72.5%) 0.774
0.94 (0.64–1.36)
0.067
1.61 (0.98–2.65)
0.595
1.10 (0.78–1.56)
For each variable, the number of patients included is given. Footnotes: see Table 4 and 5 for details.
doi:10.1371/journal.pone.0014466.t007
Table 8. Significant CD phenotype associations of rs2066843
and rs2076756 as shown in Tables 5, 6 and 7 stratified for
the presence (NOD2+) or absence (NOD2-) of the three
CD-associated NOD2 mutations p.Arg702Trp (rs2066844),
p.Gly908Arg (rs2066847), and p.Leu1007fsX1008 (rs2066847).
NOD2+
n( % )
NOD2-
n (%) p value
rs2066843-TT carriers
Surgery
because of CD
65/95 (68.4%) 11/21 (52.4%) 0.206
NOD2+
n( % )
NOD2-
n( % )
rs2076756-GG carriers
Surgery
because of CD
67/96 (69.8%) 9/14 (64.3%) 0.759
B3 63/96 (65.6%) 8/13 (61.5%) 0.765
Fistulas 63/96 (65.6%) 8/13 (61.5%) 0.765
doi:10.1371/journal.pone.0014466.t008
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were independent of the presence of the three common NOD2
variants p.Arg702Trp, p.Gly908Arg, and p.Leu1007fsX1008, the
observed associations demonstrate similarities to the phenotype as
previously shown to be related to the three common NOD2
variants in our cohort [21,22]. The explorative character of our
study has to be acknowledged. Given the large number of
associations investigated, most associations would loose signifi-
cance following Bonferroni correction. However, considering the
size of our cohort and given that the highest percentages of carriers
with ileocolonic involvement, stenoses, fistulas, and CD-related
surgery were found without exception among the homozygous
carriers of these two novel NOD2 SNPs, an association with a
severe CD phenotype is very likely. Moreover, this result has to be
seen in the background of a study population of a tertiary referral
center with a very high percentage of severe CD demonstrated by
fistulas and stenoses and CD-related surgery in more than half of
the study population regardless of the genotype. These phenotypic
associations found in homozygous carriers of these SNPs were
demonstrated with similar frequencies in the subgroup of CD
patients with additional CD-associated NOD2 mutations and in
patients without these mutations, suggesting a specific disease-
modifying effect of rs2066843 and rs2076756.
Our findings highlight the essential role of the NOD2 region as
CD susceptibility gene encoding a protein which acts as sensor for
bacterial muramyl dipeptide (MDP) in the cell wall of Gram-
positive and Gram-negative bacteria [8,15,16,17]. However, the
exact mechanism how NOD2 variants influence the intestinal
inflammation is still under investigation. First, NOD2 mutations
are associated with diminished mucosal alpha-defensin expression
in CD [33], although this finding is challenged by the results of a
recent study [34], demonstrating that in ileal CD reduced alpha-
defensin expression is the result of inflammation and not of NOD2
mutation status. Second, there is evidence for an impaired
dendritic cell function in CD patients with NOD2 variants [35]
and a loss of synergy between TLR9 and NOD2 in innate immune
responses to CpG DNA [36]. Third, there might be cross-
tolerization between NOD1 and NOD2 leading to increased
recognition of both pathogenic and commensal bacteria in
NOD2-deficient macrophages pre-exposed to microbial ligands
[37]. Fourth, the study by Kobayashi et al. demontrated that Nod2-
deficient mice are more susceptible to bacterial infection and thus
Nod2 protein is a critical regulator of bacterial immunity within
the intestine [38]. Finally, very recent evidence suggests that
NOD1 and NOD2 are essential for recruitment of ATG16L1
during bacterial infection [31], which is impaired in patients with
CD-associated NOD mutants [31]. We therefore analyzed CD-
associated NOD2 and ATG16L1 variants for epistasis. However, we
found no evidence for significant gene-gene interactions between
these variants regarding CD susceptibility. This is in line with
another large study demonstrating no epistasis for the three main
CD-associated NOD2 variants and ATG16L1 [39], while another
study found a weak gene-gene interaction between the ATG16L1
variant rs2241880 and the three common CD-associated NOD2
variants (p=0.039) [14].
Despite the growing evidence for a strong genetic background in
IBD by various genome-wide analyses and cohort studies
[7,11,13,14,40,41,42,43,44], CD still remains a complex disorder
modulated not only by susceptibility genes but also influenced by
environmental factors. Moreover, there are genetic differences
between different ethnic cohorts. For example, studies in Asian
CD cohorts [45,46] could not show any evidence for a role of
NOD2 in CD susceptibility in Asian populations. Genetic
counselling based on the NOD2 genotype as well as the analysis
of environmental risk factors could therefore benefit the individual
at risk and change daily clinical practice.
Taken together, we conclude that the identification of the two
novel NOD2 variants rs2066843 and rs2076756 might have
implications for the future risk assessment in CD patients,
considering their high minor allele frequencies among Caucasian
CD patients and the association with a severe disease phenotype.
However, the association of these two NOD2 variants with CD was
less pronounced than that with rs2066847 (p.Leu1007fsX1008)
which demonstrated even a more severe phenotypic effect than
rs2066843 and rs2076756 in our previous studies [21,22]. So far, a
major functional effect on the NF-kB pathway has only be shown
for the p.Leu1007fsX1008 variant
6. Therefore, further functional
analyses of rs2066843 and rs2076756 as well as detailed genotype-
phenotype analyses in very large cohorts including a comprehen-
sive assessment of low frequency variants in the NOD2 gene region
are needed to clarify the contribution of these novel variants to the
pathogenesis of CD. Currently, these two novel variants will not
replace the other common CD-associated NOD2 variants
p.Arg702Trp (rs2066844), p.Gly908Arg (rs2066847), and
p.Leu1007fsX1008 (rs2066847) when evaluating genetic risk
factors in CD patients.
Supporting Information
Table S1 Primer sequences, FRET probe sequences and primer
annealing temperatures used for genotyping of NOD2 variants
rs2066843 and rs2076756. Note: FL: Fluorescein, LC640: Light-
Cycler Red 640, LC670: LightCycler Red 670; the polymorphic
position within the sensor probe is underlined. A phosphate is
linked to the 39-end of the acceptor probe to prevent elongation by
the DNA polymerase in the PCR.
Found at: doi:10.1371/journal.pone.0014466.s001 (0.02 MB
DOC)
Table S2 Primer sequences used for sequence analysis of NOD2
variants rs2066843 and rs2076756.
Found at: doi:10.1371/journal.pone.0014466.s002 (0.02 MB
DOC)
Table S3 Allele frequencies of the SNPs rs2066843 and
rs2076756 in patients with Crohn’s disease (CD), ulcerative colitis
(UC) and controls in the initial discovery cohort from the
University Hospital Munich-Grosshadern. Minor allele frequen-
cies (MAF), allelic test P-values, and odds ratios (OR, shown for
the minor allele) with 95% confidence intervals (CI) are depicted
for both the CD and UC case-control cohorts.
Found at: doi:10.1371/journal.pone.0014466.s003 (0.03 MB
DOC)
Table S4 Allele frequencies of the NOD2 SNPs in patients with
Crohn’s disease (CD), ulcerative colitis (UC) and controls from the
replication cohort of the University Hospital Munich, Campus
Innenstadt and Ruhr-University Bochum. Minor allele frequencies
(MAF), allelic test P-values, and odds ratios (OR, shown for the
minor allele) with 95% confidence intervals (CI) are depicted for
both the CD and UC case-control cohorts.
Found at: doi:10.1371/journal.pone.0014466.s004 (0.03 MB
DOC)
Table S5 LD matrix for NOD2 SNPs in CD patients. Values
are given as D’/r
2.
Found at: doi:10.1371/journal.pone.0014466.s005 (0.02 MB
DOC)
Table S6 LD matrix for NOD2 SNPs in UC patients. Values
are given as D’/r
2.
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DOC)
Table S7 LD matrix for NOD2 SNPs in controls. Values are
given as D’/r
2.
Found at: doi:10.1371/journal.pone.0014466.s007 (0.03 MB
DOC)
Table S8 Haplotype-analysis for NOD2 SNPs in the UC patient
cohort. Only omnibus p-values are presented, given that none of
these haplotypes showed significant disease association.
Found at: doi:10.1371/journal.pone.0014466.s008 (0.02 MB
DOC)
Table S9 Analysis for epistasis between SNPs rs2066843,
rs2066843, rs2066844 (p.Arg702Trp), rs2066845 (p.Gly908Arg)
and rs2066847 (p.Leu1007fsX1008) in the NOD2 gene and the
SNP rs2241880=p.Thr300Ala within the ATG16L1 gene
regarding CD susceptibility. *All p values given are uncorrected
for multiple comparisons.
Found at: doi:10.1371/journal.pone.0014466.s009 (0.02 MB
DOC)
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